Compare Kroger Co (KR) vs Moderna, Inc. (MRNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kroger Co vs Moderna, Inc. — how do they compare? Kroger Co trades at $60.87 (market cap $36.27B), while Moderna, Inc. trades at $224.92 (market cap $78.65B). The key difference: Moderna, Inc. is far larger — about 2.2× Kroger Co's market cap, and Kroger Co pays a 2.54% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kroger Co for 108 Days and Moderna, Inc. for 59 Days on average.
| KR | MRNA | |
|---|---|---|
Market Cap | $36.27B | $78.65B |
Volume | 8,301,523 | 37,373,437 |
Sector | Consumer Staples | Health |
52-Week High | $75.60 | $203.46 |
52-Week Low | $55.53 | $22.36 |
Typical Hold Time | 108 Days | 59 Days |
Enterprise Value | $57.69B | $74.80B |
Dividend Yield | 2.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kroger (KR) trades at $61.64, up 4.03% today, with a bullish technical signal supported by moving averages. The stock shows mixed fundamentals with a low P/S ratio of 0.26 but elevated P/E of 33.19, while recent earnings beat expectations in two of the last three quarters. Analyst consensus is moderately bullish with a $70.62 price target, representing 14.6% upside potential from current levels.
Kroger offers value through its low valuation multiples and consistent dividends, but faces headwinds from competitive pressures and integration risks from pending acquisitions. The company's digital growth initiatives and retail media expansion provide growth catalysts, though margin compression remains a concern amid rising costs and softer sales guidance for fiscal 2026.
Moderna (MRNA) trades at $225.00, up 14.52% in 24 hours, approaching its 52-week high. The stock shows strong technical momentum with bullish moving averages and support at $194. Fundamentally, while revenue has declined from pandemic peaks to $1.92B in 2025, the company continues to beat EPS expectations and maintains a robust pipeline in oncology and respiratory vaccines. Recent inclusion in the Nasdaq-100 index has generated positive momentum, though valuation metrics remain elevated with a P/S ratio of 35.08.
Outlook remains bifurcated - significant growth potential exists in the cancer vaccine pipeline and respiratory vaccine expansion, but current valuations appear stretched relative to financial performance. Key risks include execution challenges in new therapeutic areas, competitive pressure from Pfizer/BioNTech, and dependence on pipeline success beyond COVID-19 vaccines. Analyst consensus shows cautious optimism with a $115.70 price target despite recent downgrades.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kroger Co
Kroger is the leading American grocer, with 2,726 supermarkets operating under several banners throughout the country as of the end of fiscal 2021. Around 83% of stores have pharmacies, while nearly 60% also sell fuel. The company also operates roughly 120 fine jewelry stores. Kroger features a leading private-label offering and manufactures around 30% of its own-brand units (and more than 40% of its grocery own-label assortment) itself, in 33 food production plants nationwide. Kroger is a top-two grocer in most of its major markets (as of early 2021, according to company data). Virtually all of Kroger's sales come from the United States.
Read more on KR →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
